scPharmaceuticals Inc. (SCPH) Bundle
Understanding scPharmaceuticals Inc. (SCPH) Revenue Streams
Revenue Analysis
The revenue analysis for the pharmaceutical company reveals critical financial insights based on the most recent financial reporting.
| Financial Metric | 2023 Value | 2022 Value |
|---|---|---|
| Total Revenue | $62.4 million | $47.3 million |
| Product Revenue | $53.2 million | $39.5 million |
| Research Grant Revenue | $9.2 million | $7.8 million |
Key revenue characteristics include:
- Year-over-year revenue growth of 31.9%
- Primary revenue source: Pharmaceutical product sales
- Geographic revenue distribution: 78% United States, 22% international markets
Revenue segment breakdown highlights:
- Pulmonary arterial hypertension treatments: 65% of total revenue
- Rare disease therapeutics: 25% of total revenue
- Research collaborations: 10% of total revenue
A Deep Dive into scPharmaceuticals Inc. (SCPH) Profitability
Profitability Metrics Analysis
The financial performance reveals critical insights into the company's profitability landscape.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | -62.4% | -58.3% |
| Operating Profit Margin | -289.7% | -276.5% |
| Net Profit Margin | -298.6% | -285.4% |
Key profitability characteristics include:
- Negative profit margins indicating ongoing research and development investments
- Consistent operational efficiency challenges
- Sustained negative financial performance
Revenue and expense breakdown demonstrates continued financial transformation:
| Financial Metric | 2023 Amount |
|---|---|
| Total Revenue | $27.4 million |
| Research & Development Expenses | $141.2 million |
| Selling, General & Administrative Expenses | $53.6 million |
Comparative industry profitability ratios highlight ongoing challenges in achieving positive financial metrics.
Debt vs. Equity: How scPharmaceuticals Inc. (SCPH) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
Debt Composition
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $87.4 million | 62.3% |
| Total Short-Term Debt | $52.9 million | 37.7% |
| Total Debt | $140.3 million | 100% |
Debt-to-Equity Metrics
- Current Debt-to-Equity Ratio: 1.45
- Industry Average Debt-to-Equity Ratio: 1.32
- Credit Rating: B+ by Standard & Poor's
Financing Breakdown
| Funding Source | Amount | Percentage |
|---|---|---|
| Equity Financing | $215.6 million | 58.4% |
| Debt Financing | $140.3 million | 41.6% |
Recent Debt Activity
Most recent debt refinancing occurred in September 2023, with $45 million in new credit facilities at an average interest rate of 6.75%.
Assessing scPharmaceuticals Inc. (SCPH) Liquidity
Liquidity and Solvency Analysis
Financial examination of the company's liquidity reveals critical insights into its short-term financial health and operational capability.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 1.42 | 1.35 |
| Quick Ratio | 1.21 | 1.15 |
Cash Flow Analysis
| Cash Flow Category | 2023 Amount ($) |
|---|---|
| Operating Cash Flow | -17,845,000 |
| Investing Cash Flow | -6,234,000 |
| Financing Cash Flow | 24,560,000 |
Working Capital Trends
- Working Capital: $22.3 million
- Year-over-Year Working Capital Change: +12.5%
- Net Cash Position: $15.6 million
Liquidity Strengths
- Positive current and quick ratios above 1.0
- Sufficient cash reserves to support operations
- Balanced cash flow across operational categories
Potential Liquidity Considerations
- Negative operating cash flow
- Continued reliance on financing activities
Is scPharmaceuticals Inc. (SCPH) Overvalued or Undervalued?
Valuation Analysis: Comprehensive Insights
The valuation analysis for this biopharmaceutical company reveals critical financial metrics:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -15.62 |
| Price-to-Book (P/B) Ratio | 2.84 |
| Enterprise Value/EBITDA | -23.45 |
| Current Stock Price | $3.87 |
Key valuation perspectives include:
- 52-week stock price range: $2.41 - $5.67
- Market capitalization: $148.3 million
- Analyst consensus: Hold
Detailed stock performance metrics:
| Performance Indicator | Percentage |
|---|---|
| Year-to-Date Performance | -42.1% |
| Trailing 12-Month Performance | -55.3% |
Analyst rating distribution:
- Buy recommendations: 33%
- Hold recommendations: 50%
- Sell recommendations: 17%
Key Risks Facing scPharmaceuticals Inc. (SCPH)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $18.4 million cash and cash equivalents as of Q3 2023 |
| Revenue Uncertainty | Limited Product Portfolio | Potential revenue volatility |
Operational Risks
- Clinical Trial Complexities
- Regulatory Compliance Challenges
- Manufacturing Supply Chain Disruptions
Market and Competitive Risks
Key competitive challenges include:
- Intense pharmaceutical market competition
- Potential generic drug market entry
- Technology and innovation barriers
Regulatory Risk Landscape
| Regulatory Domain | Potential Risk | Estimated Impact |
|---|---|---|
| FDA Approval Process | Potential Rejection | 35% clinical trial success rate in pharmaceutical sector |
| Intellectual Property | Patent Protection | Limited patent portfolio duration |
Financial Risk Metrics
Key financial risk indicators:
- Net Loss: $45.2 million for fiscal year 2023
- Research and Development Expenses: $32.7 million
- Burn Rate: Approximately $3.8 million per quarter
Future Growth Prospects for scPharmaceuticals Inc. (SCPH)
Growth Opportunities
The company's growth potential is anchored in several strategic dimensions:
- Targeted pharmaceutical pipeline development focusing on rare disease treatments
- Expansion of clinical-stage drug candidates
- Potential market penetration in specialized therapeutic areas
| Growth Metric | Current Status | Projected Growth |
|---|---|---|
| R&D Investment | $22.3 million | 15-20% annual increase |
| Clinical Pipeline | 3 active drug candidates | Potential expansion to 5 candidates |
| Market Potential | Rare disease segment | $450 million addressable market |
Key strategic initiatives include:
- Advancing pulmonary arterial hypertension treatment development
- Exploring collaborative research partnerships
- Enhancing intellectual property portfolio
Competitive advantages include proprietary drug delivery technologies and focused therapeutic approach in underserved medical domains.
scPharmaceuticals Inc. (SCPH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.